New Retina Radio by Eyetube

New Retina Radio by Eyetube

Retina Today
Country USA
Language EN-US
Episodes 246
Latest 19.11.2026

New Retina Radio is a podcast that features stories about retina that are not told elsewhere. It is produced by Retina Today and covers topics related to retina health and treatments.

Episodes

  • When Is Isolated PAMM Urgent?
    When Is Isolated PAMM Urgent? 19.11.2026 16m
    When a paracentral acute middle maculopathy (PAMM) lesion turns up on OCT, is it a retinal finding or a harbinger of something more serious? Barton Blackerby, MD; Matt Starr, MD; and Kyle Kovacs, MD, review a study by Hosovsky and colleagues published in Ophthalmology quantifying the yield of systemic workup in patients with acute isolated PAMM and explore its implications for real-world practice. They discuss how urgency should be stratified for acute versus incidental PAMM findings, what a workup looks like for younger patients presenting without traditional cardiovascular risk factors, and...
  • The Fellow Eye: Episode 8
    The Fellow Eye: Episode 8 05.11.2026 45m
    Co-hosts Justin C. Muste, MD, and David Fell, MD, discuss the endophthalmitis endgame with Jordan Deaner, MD, a retina specialist at Wills Eye Hospital, and Wills Eye retina fellows Collin Richards, MD, and Erik Massenzio, MD. They share the best timing and treatment approach to patients who present with post-cataract and post-injection endophthalmitis. Shared cases help illustrate when to tap-and-inject (you will never regret doing it, but you might regret not doing it), when vitrectomy is warranted, the challenges of fungal endophthalmitis, and more.
  • AAO '26: BRUNELLO and LUGANO
    AAO '26: BRUNELLO and LUGANO 29.10.2026 24m
    Could a Wnt pathway agonist match anti-VEGF therapy for DME, and what should we make of a phase 3 trial that hit its anatomic goals but missed its primary visual endpoint? Don D’Amico, MD, reviews one-year results from the phase 2b/3 BRUNELLO study of remigromig (Restoret, Merck/EyeBio), a Wnt pathway agonist, for diabetic macular edema. And Carl Regillo, MD, discusses the phase 3 LUGANO study of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet AMD, which missed its primary endpoint despite reducing treatment burden by 42%.
  • AAO '26: Fluid Debates in Wet AMD + OTX-TKI for Wet AMD
    AAO '26: Fluid Debates in Wet AMD + OTX-TKI for Wet AMD 22.10.2026 28m
    The debates at AAO Retina Subspecialty Day have a reputation for examining unresolved issues. Where did the debate on whether wet AMD tolerates fluid land? Avni Finn, MD, joined the show to recap her side of the wet AMD fluid debate—and shared what the opposite side had to argue, too. How well does she buy her own argument? And Darius Moshfeghi, MD, joins the show to share findings from the SOL-1 study examining OTX-TKI (Ocular Therapeutix) for wet AMD. What did the researchers find? And how did the study authors leverage AI to simulate real-world treatment activity? Join us on this episode to...
  • PPV vs Phacovitrectomy for RRD in Phakic Eyes
    PPV vs Phacovitrectomy for RRD in Phakic Eyes 15.10.2026 12m
    Does phacovitrectomy improve outcomes over conventional PPV for rhegmatogenous retinal detachment repair in a phakic eyes? Or does it introduce unnecessary complexity? Vaidehi Dedania, MD; Yewlin Chee, MD; and Joshua Uhr, MD, review results from a multicenter cohort study published in Ophthalmology Retina and discuss whether the study's findings have any bearing on real-world decision-making, parse generational differences regarding perceived phacovitrectomy risks, and review whether changes to technology during the course of the study may have affected the findings.
  • The Fellow Eye: Episode 7
    The Fellow Eye: Episode 7 01.10.2026 35m
    Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Matthew Starr, MD, a vitreoretinal surgeon at the Mayo Clinic, and Timothy Xu, MD, a retina fellow at Wills Eye Hospital, to discuss retained lens fragments and secondary IOLs. They share complex cases, when to consider following patients medically, surgical techniques for removing fragments, and how to make the best secondary lens choice.
  • Spotlight on UNITY® VCS: 50 Cases In
    Spotlight on UNITY® VCS: 50 Cases In 24.09.2026 22m
    In this episode of RetinaLive focused on UNITY® VCS|CS, Matt Cunningham, MD, FASRS, welcomes Steven Yeh, MD, FASRS for a reflection on early clinical experience with the UNITY® VCS system following the first 50 cases. The discussion highlights real-world insights on surgical efficiency, fluidics stability, and intraoperative control across a range of case complexities. From seamless OR integration to advancements in 27-gauge instrumentation and laser delivery, the conversation offers practical perspectives on adoption, training, and how evolving technology can enhance surgeon confidence and pa...
  • Vitreous Hemorrhage Following PVD: Who Needs Surgery?
    Vitreous Hemorrhage Following PVD: Who Needs Surgery? 18.09.2026 15m
    How aggressively should you manage a vitreous hemorrhage after a PVD when you can't see the retina underneath it? Barton Blackorby, MD, moderates a discussion with Matt Starr, MD, and Kyle Kovacs, MD, about a study published in Ophthalmology by Hasbolat et al examining 366 patients with PVD-related vitreous hemorrhage initially managed with observation. The panel discusses how exam technique and B-scan reliance may affect detachment detection rates, debates follow-up intervals given that most retinal detachments in the study occurred within the first 3 weeks, and shares their own thresholds fo...
  • Spotlight on UNITY® VCS: Breaking New Ground
    Spotlight on UNITY® VCS: Breaking New Ground 10.09.2026 13m
    In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD is joined by Nina Berrocal, MD for a forward-looking discussion on adopting next-generation surgical technology. The conversation explores how UNITY® VCS is enabling innovation in a new retina practice setting, with a focus on fluidics stability, integrated anterior and posterior segment capabilities, and enhanced intraoperative efficiency. Through real-world perspectives, the episode highlights the role of advanced technology in simplifying surgical workflows, and supporting the training of the next generation of retina s...
  • ASRS '26: ArMaDa/GARDian Results and Real-World YAG Complication Incidence
    ASRS '26: ArMaDa/GARDian Results and Real-World YAG Complication Incidence 27.08.2026 16m
    Can a single molecule treat both GA and Stargardt Disease? And if so, how far along is the research? Jay Chhablani, MD, joins New Retina Radio to share data from ArMaDa and GARDian, which assessed OCU410 (Ocugen) in geographic atrophy and Stargardt disease, respectively. And Jordan Deaner, MD, sits down to discuss his research on real-world retinal tears and detachments following YAG capsulotomy. What are the actual incidence rates? And what risk factors were identified? Stick with us to find out.
  • Comparing Ocular AEs in Next-Gen Treatments
    Comparing Ocular AEs in Next-Gen Treatments 20.08.2026 13m
    What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the cas...
  • The Story Behind LYTENAVA™: From FDA Approval to Retina Practice
    The Story Behind LYTENAVA™: From FDA Approval to Retina Practice 18.08.2026 11m
    In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA. Intended for a US audience only. Spon...
  • The Fellow Eye: Episode 6
    The Fellow Eye: Episode 6 13.08.2026 41m
    Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Monia Reding, MD, a retina fellow at Casey Eye Institute, and Benjamin Young, MD, assistant professor of Ophthalmology at Casey Eye Institute, to talk about lasers. They share the pros and cons of slit-lamp laser and indirect, ergonomics, laser settings, difficult scenarios, and the personal experiences that shape their practice patterns.
  • ASRS '26: SOL-1 and TRUCKEE at 4.5 Years
    ASRS '26: SOL-1 and TRUCKEE at 4.5 Years 05.08.2026 24m
    Could TKIs be the game-changing therapy that makes wet AMD treatment less burdensome? Dilsher Dhoot, MD, joins the show to examine the SOL-1 study, a superiority study assessing the safety, efficacy, and durability of axitinib (Axpaxli, Ocular Therapeutix) for the treatment of wet AMD. And Carl Danzig, MD, stops by to deliver the 4.5-year data from TRUCKEE, which tells us how real-world patients with wet AMD perform when dosed with faricimab (Vabysmo, Genentech/Roche). How are patients doing after 3, 6, or even 9 doses? Stick with us to find out.
  • New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB Removal
    New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB Removal 16.07.2026 16m
    What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.
  • Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy
    Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy 08.07.2026 16m
    What stands between a patient with geographic atrophy and consistent, effective treatment? And how do clinicians bridge that gap? In episode 3 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, address injection burden, insurance hurdles, and the role of patient education tools in supporting adherence. The group also weighs the potential for AI to guide treatment decisions and track progression, then works through a hypothetical case of an 82-year-old caregiver with bilateral diffuse trickling GA who is not ye...
  • Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy
    Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy 08.07.2026 18m
    How have 3 years of real-world experience with complement inhibition changed when and how retina specialists treat GA? In episode 2 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, examine how referral patterns, safety data, and extension study findings have shifted their approach to early treatment. The group then works through a hypothetical case of an active 73-year-old patient with extrafoveal GA and intermediate AMD in the fellow eye, exploring how lesion characteristics, CNV risk counseling, and months...
  • Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy
    Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy 08.07.2026 13m
    Which imaging biomarkers matter most at diagnosis of GA, and how should they shape the decision to treat? In episode 1 of the GA in Practice miniseries on New Retina Radio, moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review the practical role of fundus autofluorescence and OCT in identifying high-risk GA, discuss ellipsoid zone integrity as an emerging endpoint, and work through a hypothetical case of an active, motivated patient with bilateral extrafoveal GA and good vision to explore how lifestyle, lesion characteristics, and patient education factor int...
  • The Fellow Eye: Episode 5
    The Fellow Eye: Episode 5 01.07.2026 39m
    Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Omesh P. Gupta, MD, retina specialist at Wills Eye Hospital, and Shane Griffin, MD, MCR, vitreoretinal surgery fellow at the University of California San Diego Shiley Eye Institute, to discuss scleral-fixating secondary IOLs. They share pearls for implantation success, advanced techniques, and tricks for handling complicated cases.
  • Retinal Perfusion, Sensitivity, and Function in DR
    Retinal Perfusion, Sensitivity, and Function in DR 26.06.2026 15m
    Does retinal capillary non-perfusion reliably predict functional vision loss in DR? And does the answer change how retina specialists treat it? In this episode of New Retina Radio Journal Club with VBS, Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD, discuss a prospective longitudinal cohort study examining the association between retinal sensitivity and perfusion over 2 years in patients with DR.

Popular in

The podcast also appears in the podcast charts of these countries.